Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children—the Polish Pediatric Leukemia and Lymphoma Study Group experience

BackgroundGemtuzumab ozogamicin (GO), one of the first targeted drugs used in oncology, consists of an anti-cluster of differentiation 33 (CD33) monoclonal antibody bound to a derivative of cytotoxic calicheamicin. After the drug withdrawn in 2010 due to a significantly higher rate of early deaths,...

Descripció completa

Dades bibliogràfiques

Autors principals:	Katarzyna Pawinska-Wasikowska, Malgorzata Czogala, Szymon Skoczen, Marta Surman, Monika Rygielska, Teofila Ksiazek, Agnieszka Pac, Aleksandra Wieczorek, Jolanta Skalska-Sadowska, Magdalena Samborska, Jacek Wachowiak, Radoslaw Chaber, Renata Tomaszewska, Tomasz Szczepanski, Karolina Zielezinska, Tomasz Urasinski, Malgorzata Moj-Hackemer, Krzysztof Kalwak, Marta Kozlowska, Ninela Irga-Jaworska, Walentyna Balwierz, Karolina Bukowska-Strakova
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2023-12-01
Col·lecció:	Frontiers in Immunology
Matèries:	acute myeloid leukemia gemtuzumab ozogamicin relapse refractory children immunotherapy
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1268993/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!